1. Search Result
Search Result
Results for "

brain concentration

" in MedChemExpress (MCE) Product Catalog:

70

Inhibitors & Agonists

2

Fluorescent Dye

1

Biochemical Assay Reagents

3

Peptides

1

Inhibitory Antibodies

12

Natural
Products

3

Isotope-Labeled Compounds

2

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B2150

    4-Hydroxyphenazone; NSC 174055

    Drug Metabolite Others
    4-Hydroxyantipyrine (4-Hydroxyphenazone; NSC 174055) is the major metabolite of Antipyrine (HY-B0171), can be as a biodistribution promoter. 4-Hydroxyantipyrine can increase distribution of concentration ratio of Citicoline and Antipyrine in the brain .
    4-Hydroxyantipyrine
  • HY-100921

    N-Acetylaspartylglutamic acid

    Endogenous Metabolite Neurological Disease
    Spaglumic Acid (N-Acetylaspartylglutamic acid) is a neuropeptide found in millimolar concentrations in brain.
    Spaglumic Acid
  • HY-108295

    CXB-722

    GABA Receptor Neurological Disease
    Pivagabine (CXB 722) is a hydrophobic 4-aminobutyric acid derivative with neuromodulatory activity. Pivagabine penetrates the blood-brain barrier in rats. Pivagabine antagonizes the effects of foot shock on both GABAA receptor function and corticotropin-releasing factor (CRF) concentrations in rat brain .
    Pivagabine
  • HY-B2150S

    4-Hydroxyphenazone-d3; NSC 174055-d3

    Drug Metabolite Isotope-Labeled Compounds Others
    4-Hydroxyantipyrine-d3 is the deuterium labeled 4-Hydroxyantipyrine. 4-Hydroxyantipyrine is the major metabolite of Antipyrine, can be as a biodistribution promoter. 4-Hydroxyantipyrine can increase distribution of concentration ratio of Antipyrine in the brain .
    4-Hydroxyantipyrine-d3
  • HY-100921A

    N-Acetylaspartylglutamic acid trisodium

    Endogenous Metabolite Neurological Disease Inflammation/Immunology
    Spaglumic Acid (N-Acetylaspartylglutamic acid) trisodium is a neuropeptide that exists in millimolar concentrations in the brain and possesses anti-allergic activity .
    Spaglumic Acid trisodium
  • HY-100921R

    N-Acetylaspartylglutamic acid (Standard)

    Reference Standards Endogenous Metabolite Neurological Disease
    Spaglumic Acid (Standard) is the analytical standard of Spaglumic Acid. This product is intended for research and analytical applications. Spaglumic Acid (N-Acetylaspartylglutamic acid) is a neuropeptide found in millimolar concentrations in brain.
    Spaglumic Acid (Standard)
  • HY-10550B

    XR9576 dimesylate

    P-glycoprotein Cardiovascular Disease Others
    Tariquidar dimesylate (XR9576 dimesylate) is a P-glycoprotein (P-gp) inhibitor. Tariquidar dimesylate increases the concentration of the drug in the brain by binding to P-glycoprotein, preventing it from transporting the drug from inside to outside the brain. Tariquidar dimesylate can be used in the study of blood-brain barrier penetration and multidrug resistance .
    Tariquidar dimesylate
  • HY-111142

    Others Others
    COR 32-24 is a compound that enters the brain through the purine transport system and has the activity of being transported by this system. The brain uptake index of COR 32-24 in rats decreases with the increase of the concentration of unlabeled compound, and its affinity for purine transporters is higher than that for adenine.
    COR 32-24
  • HY-163474

    Monoamine Oxidase Neurological Disease
    MAO-B-IN-32 is an inhibitor of MAO-B (IC50 = 16 nM).MAO-B-IN-32 increases dopamine concentration in the brain by inhibiting MAO-B activity .
    MAO-B-IN-32
  • HY-116211

    WIN-25978

    Biochemical Assay Reagents Neurological Disease
    Amfonelic acid (WIN-25978) is a highly selective dopamine reuptake inhibitor. Amfonelic acid interferes with the in vitro neuronal uptake of norepinephrine in the iris of rats, but does not alter the concentrations of norepinephrine or dopamine in the whole mouse brain. Amfonelic acid can be used as a pharmacological tool to study the brain reward system, dopamine pathway and dopamine transporter .
    Amfonelic acid
  • HY-13909
    RGFP966
    40+ Cited Publications

    HDAC Cancer
    RGFP966 is a highly selective HDAC3 inhibitor with an IC50 of 80 nM and shows no inhibition to other HDACs at concentrations up to 15 μM. RGFP966 can penetrate the blood brain barrier (BBB).
    RGFP966
  • HY-168167

    Endogenous Metabolite Neurological Disease
    BuChE-IN-14 is a novel compound that selectively inhibits acetylcholinesterase (AChE) activity. BuChE-IN-14 showed a concentration-dependent inhibitory effect on AChE in rat brain in vitro experiments. BuChE-IN-14 can increase the extracellular acetylcholine (ACh) concentration in the rat hippocampus and striatum at a certain dose. BuChE-IN-14 may help improve memory impairment caused by cholinergic dysfunction .
    BuChE-IN-14
  • HY-107562

    Histamine Receptor Neurological Disease
    JNJ-10181457 is a neutral, potent, brain-penetrant and selective non-imidazole H3 antagonist which increases NE and ACh concentrations in rat frontal cortex. JNJ-10181457 can be used for neurological research .
    JNJ 10181457 dihydrochloride
  • HY-124634
    PZ-2891
    1 Publications Verification

    PANK Neurological Disease
    PZ-2891 is an orally bioavailable, brain penetrant pantothenate kinase (PANK) modulator. PZ-2891 act as an orthosteric inhibitor at high concentrations and an allosteric activator at lower sub-saturating concentrations. PZ-2891 inhibits human pantothenate kinases PANK1β, PANK2, and PANK3 with IC50s of 40.2 nM, 0.7 nM and 1.3 nM, respectively .
    PZ-2891
  • HY-110180

    mGluR Neurological Disease
    VU0409106 is a potent and selective mGlu5 negative allosteric modulator (NAM) with an IC50 of 24 nM. VU0409106 shows anxiolytic effects in rat models in a concentration-dependent manner. VU0409106 also penetrates the blood-brain barrier (BBB) .
    VU0409106
  • HY-W023493

    2-Aminopent-4-enoic acid

    Amino Acid Decarboxylase Neurological Disease
    DL-Allylglycine (2-Aminopent-4-enoic acid) is a glutamate decarboxylase (GAD) inhibitor. DL-Allylglycine significantly increases mouse brain ornithine decarboxylase (ODC) activity and decreases S-adenosyl-L-methionine decarboxylase (SAM-DC) activity. DL-Allylglycine causes a marked decrease in brain GABA concentration. DL-Allylglycine has convulsant activity that can be used in studies to induce epileptic seizures .
    DL-Allylglycine
  • HY-W338446

    Tau Protein Neurological Disease
    BF-170 is a selective tau fibril binding agent with an EC50 of 221 nM. It exhibits good blood-brain barrier permeability, and after intravenous injection in mice, the concentration in brain tissue reaches 9.1% ID/g within 2 minutes (with a brain clearance rate of 0.25% ID/g after 30 minutes). BF-170 can be used as a probe for tau protein pathology imaging in Alzheimer's disease (AD). It plays an important role in early-stage AD research and holds potential for imaging studies of tau-related neurodegenerative diseases .
    BF-170
  • HY-101282

    Amyloid-β Neurological Disease
    Glutaminyl Cyclase Inhibitor 3 (compound 212 ), a designed anti-Alzheimer’s compound, is a potent human Glutaminyl Cyclase (GC) inhibitor, with an IC50 of 4.5 nM. Glutaminyl Cyclase-IN-1 (compound 212) significantly reduced the brain concentrations of pyroform Aβ and total Aβ and restored cognitive functions .
    Glutaminyl Cyclase Inhibitor 3
  • HY-157227

    VPC4

    TRP Channel Inflammation/Immunology
    VPC01091.4 (VPC4) is a TRPM7 inhibitor and blocks TRPM7 current at low micromolar concentrations. VPC01091.4 can penetrate the blood-brain barrier. VPC01091.4 is an efficacious anti-inflammatory agent that arrests systemic inflammation in vivo .
    VPC01091.4
  • HY-P11226

    Amyloid-β CaMK Apoptosis Neurological Disease
    TI-16 is a peptide that targets β-amyloid (Aβ) protein. TI-16 can cross the blood-brain barrier. TI-16 can increase the concentration of intracellular free CaM, thereby restoring calcium ion homeostasis and reducing Aβ toxicity. TI-16 can reduce the deposition of Aβ in the brain, improve neuronal pathology, inhibit cell apoptosis, and improve cognitive function in mice. TI-16 is commonly used in the study of Alzheimer's disease .
    TI-16
  • HY-DY1016

    Fluorescent Dye Others
    FITC-Dextran (MW 10000) (solution) is a fluorescent probe for fluorescein isothiocyanate (FITC) dextran (Ex=495 nm; Em=525 nm). FITC-Dextran (MW 10000) can be used as a marker to reveal heat shock-induced cell damage and to study the early and late stages of apoptosis. FITC-Dextran (MW 10000) can also be used for cell permeability studies, such as blood-brain barrier permeability and determination of the extent of blood-brain barrier disruption .
    Solution Concentration: 2 mM
    FITC-Dextran (MW 10000) (solution)
  • HY-DY1018

    Fluorescent Dye Others
    FITC-Dextran (MW 4000) (solution) is a fluorescent probe for fluorescein isothiocyanate (FITC) dextran (Ex=495 nm; Em=525 nm). FITC-Dextran (MW 4000) can be used as a marker to reveal heat shock-induced cell damage and to study the early and late stages of apoptosis. FITC-Dextran (MW 4000) can also be used for cell permeability studies, such as blood-brain barrier permeability and determination of the extent of blood-brain barrier disruption .
    Solution Concentration: 2 mM
    FITC-Dextran (MW 4000) (solution)
  • HY-W747597

    Disialoganglioside GD1b; Ganglioside C1; Ganglioside G2

    Endogenous Metabolite Cancer
    Ganglioside GD1b Disodium Salt (Bovine Brain) (Disialoganglioside GD1b; Ganglioside C1) is an acidic glycosphingolipid containing two sialic acid residues linked to an internal galactose unit. Ganglioside GD1b Disodium Salt tightly packs with cholesterol to form lipid microdomains that modulate intracellular and intercellular signaling events. Concentrations of Ganglioside GD1b Disodium Salt (Bovine Brain) in the human brain increase with age and are positively correlated with pilocytic astrocytoma tumor grade. Ganglioside GD1b Disodium Salt has been detected in various other gliomas, including primitive neuroectodermal tumors, glioblastomas, and anaplastic astrocytomas.
    Ganglioside GD1b Disodium Salt (Bovine Brain)
  • HY-P99694

    JR-171

    Transferrin Receptor Neurological Disease
    Lepunafusp alfa (JR-171) is a BBB-penetrable fusion protein consisting of J-Brain Cargo and IDUA (a lysosomal enzyme, α-L-iduronidase). Lepunafusp alfa can reduce concentration of heparan sulfate (HS) and dermatan sulfate (DS). Lepunafusp alfa can be used for research of mucopolysaccharidosis type I .
    Lepunafusp alfa
  • HY-13289A
    Nepicastat hydrochloride
    3 Publications Verification

    SYN-117 hydrochloride; RS-25560-197 hydrochloride

    Dopamine β-hydroxylase Cardiovascular Disease
    Nepicastat hydrochloride (SYN-117 hydrochloride) is a selective, potent, and orally active inhibitor of dopamine-beta-hydroxylase. Nepicastat hydrochloride produces concentration-dependent inhibition of bovine (IC50=8.5 nM) and human (IC50=9 nM) dopamine-beta-hydroxylase. Nepicastat hydrochloride can cross the blood-brain barrier (BBB) .
    Nepicastat hydrochloride
  • HY-139182

    Endogenous Metabolite Metabolic Disease
    CAY10762 is an inhibitor of monoacylglycerol lipase (MAGL; IC50=34.1 nM). It reduces hydrogen peroxide-induced lactate dehydrogenase (LDH) release from Neuro2a cells when used at a concentration of 1 μM. CAY10762 (10 mg/kg) increases levels of 2-arachidonoyl glycerol in mouse brain.
    MAGL-IN-3
  • HY-164495

    FAAH Thyroid Hormone Receptor Inflammation/Immunology Endocrinology
    Sob-AM2 is a potent substrate (Km=1.3 μM) targeting fatty acid amide hydrolase (FAAH) expressed in the brain and has blood-brain barrier permeability. Sob-AM2 delivers high concentrations of Sobetirome (HY-14823) to the central nervous system with minimal peripheral systemic dose, thereby stimulating central thyroid hormone receptor β (TRβ). In addition, Sob-AM2 can prevent myelin and axon degeneration in experimental autoimmune encephalomyelitis (EAE) mice .
    Sob-AM2
  • HY-122742

    iGluR Neurological Disease
    HBT1 is an effective AMPA receptor AMPA-R potentiator. HBT1 specifically binds to the ligand-binding domain (LBD) of AMPAR and enhances receptor activity only when AMPA is present., HBT1 has almost no agonistic effect (i.e., reaching the optimal concentration, and then the efficacy decreases as the concentration continues to increase) compared with traditional AMPA-R potentiator, avoiding the bell-shaped reaction of brain-derived neurotrophic factor (BDNF) production in primary neurons. HBT1 can be applicable to a wider range of neurological and psychiatric diseases (such as depression, Alzheimer's disease, etc.) .
    HBT1
  • HY-13289

    SYN117; RS-25560-197

    Dopamine β-hydroxylase Cardiovascular Disease
    Nepicastat (SYN117) is a selective, potent, and orally active inhibitor of dopamine-beta-hydroxylase. Nepicastat (SYN117) produces concentration-dependent inhibition of bovine (IC50=8.5 nM) and human (IC50=9 nM) dopamine-beta-hydroxylase. Nepicastat (SYN117) can cross the blood-brain barrier (BBB) .
    Nepicastat
  • HY-N6951

    Apoptosis Akt mTOR Reactive Oxygen Species (ROS) Caspase Bacterial Fungal Infection Neurological Disease Inflammation/Immunology Cancer
    Guaiazulene is a bicyclic sesquiterpene that can cross the blood-brain barrier. Guaiazulene exhibits various biological activities such as anti-inflammatory, antioxidant, hepatoprotective, antibacterial, and anti-tumor properties. Guaiazulene is also commonly used as a colorant in cosmetics. Guaiazulene shows in vitro cytotoxicity to rat neuronal cells and N2a neuroblastoma cells at high concentrations .
    Guaiazulene
  • HY-116062

    Monoamine Transporter Dopamine Transporter Adrenergic Receptor Others
    JNJ-7925476 (hydrochloride) is a triple monoamine uptake inhibitor with the ability to regulate neurotransmitter levels and antidepressant activity. JNJ-7925476 (hydrochloride) can be rapidly absorbed into the plasma in rats, with a higher concentration in the brain than in plasma. It can induce an increase in the levels of extracellular serotonin, dopamine, and norepinephrine in the rat cerebral cortex, and exhibits antidepressant activity in the mouse tail suspension test.
    JNJ-7925476 hydrochloride
  • HY-131693A

    GAG hydrochloride

    GABA Receptor Neurological Disease Cancer
    γ-Acetylenic GABA (GAG) hydrochloride is an irreversible inhibitor of GABA-transaminase. γ-Acetylenic GABA hydrochloride can increase the concentration of GABA in rat brain . γ-Acetylenic GABA (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    γ-Acetylenic GABA hydrochloride
  • HY-B2150R

    4-Hydroxyphenazone (Standard); NSC 174055 (Standard)

    Reference Standards Drug Metabolite Others
    4-Hydroxyantipyrine (Standard) is the analytical standard of 4-Hydroxyantipyrine. This product is intended for research and analytical applications. 4-Hydroxyantipyrine (4-Hydroxyphenazone; NSC 174055) is the major metabolite of Antipyrine (HY-B0171), can be as a biodistribution promoter. 4-Hydroxyantipyrine can increase distribution of concentration ratio of Citicoline and Antipyrine in the brain .
    4-Hydroxyantipyrine (Standard)
  • HY-16731

    EVT 302; RG1577; RO4602522

    Monoamine Oxidase Reactive Oxygen Species (ROS) Neurological Disease
    Sembragiline (EVT 302) is a potent, selective and reversible monoamine oxidase B (MAO-B) inhibitor. Sembragiline reduces the metabolism of dopamine and other amine neurotransmitters by inhibiting the activity of the MAO-B enzyme, thereby potentially increasing the concentration of these neurotransmitters in the brain. Inhibition of the MAO-B enzyme also reduces the formation of toxic reactive oxygen species (ROS) that play a role in the pathological process of AD. Sembragiline has good oral activity and blood-brain barrier permeability. Sembragiline can be used in studies of AD, especially in patients with AD who show increased MAO-B activity .
    Sembragiline
  • HY-134240

    Magnesium L-threonate

    NF-κB TNF Receptor Neurological Disease Inflammation/Immunology
    L-Threonic acid magnesium (Magnesium L-threonate) is the enantiomer of Threonic acid and the metabolite of vitamin C (HY-B0166). L-Threonic acid magnesium is a magnesium supplementation, that improves the brain magnesium concentration, inhibits the activation of TNF-α/NF-κB signaling pathway. L-Threonic acid magnesium can be used in research of Alzheimer’s disease. L-Threonic acid magnesium is orally active .
    L-Threonic acid magnesium
  • HY-106004

    BIA 5-1058

    Dopamine β-hydroxylase P-glycoprotein BCRP Cardiovascular Disease Cancer
    Zamicastat (BIA 5-1058) is a dopamine β-hydroxylase (DBH) inhibitor and can cross the blood-brain barrier (BBB) to cause central as well as peripheral effects. Zamicastat is also a concentration-dependent dual P-gp and BCRP inhibitor with IC50 values of 73.8 μM and 17.0 μM, respectively . Zamicastat reduces high blood pressure .
    Zamicastat
  • HY-106644

    FG4963 free acid

    5-HT Receptor Neurological Disease
    Femoxetine is a serotonin (5-HT) inhibitor with antidepressant properties. Femoxetine increases serotonin levels in the brain by preventing serotonin from being reabsorbed by nerve cells, resulting in increased concentrations of the neurotransmitter in the synaptic gap, which enhances serotonin signaling. Femoxetine can be used to study the role of serotonin in depression and other emotional disorders, and how 5-HT reuptake inhibitors affect mood and behavior .
    Femoxetine
  • HY-129982

    Apical Sodium-Dependent Bile Acid Transporter Metabolic Disease
    SC-435 is an orally effective apical sodium codependent bile acid transporter (ASBT) inhibitor. SC-435 effectively removes neurotoxic bile acids and ammonia from the blood by inhibiting intestinal ASBT, thereby alleviating liver and brain damage caused by liver failure. SC-435 can alter hepatic cholesterol metabolism and lower plasma low-density lipoprotein-cholesterol concentrations .
    SC-435
  • HY-131693

    GAG

    GABA Receptor Neurological Disease Cancer
    γ-Acetylenic GABA (4-Aminohex-5-ynoic acid) is an irreversible inhibitor of GABA-transaminase. γ-Acetylenic GABA can increase the concentration of GABA in rat brain . γ-Acetylenic GABA is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    γ-Acetylenic GABA
  • HY-13289B

    (R)-SYN117 hydrochloride; (R)-RS-25560-197 hydrochloride; RS-25560-198 hydrochloride

    Dopamine β-hydroxylase Cardiovascular Disease
    (R)-Nepicastat hydrochloride is the isomer of Nepicastat (HY-13289). Nepicastat (SYN117) is a selective,potent,and orally active inhibitor of dopamine-beta-hydroxylase. Nepicastat (SYN117) produces concentration-dependent inhibition of bovine (IC50=8.5 nM) and human (IC50=9 nM) dopamine-beta-hydroxylase. Nepicastat (SYN117) can cross the blood-brain barrier (BBB) .
    (R)-Nepicastat hydrochloride
  • HY-106644A

    FG4963

    5-HT Receptor Neurological Disease
    Femoxetine hydrochloride is a serotonin (5-HT) inhibitor with antidepressant properties. Femoxetine hydrochloride increases serotonin levels in the brain by preventing serotonin from being reabsorbed by nerve cells, resulting in increased concentrations of the neurotransmitter in the synaptic gap, which enhances serotonin signaling. Femoxetine hydrochloride can be used to study the role of serotonin in depression and other emotional disorders, and how 5-HT reuptake inhibitors affect mood and behavior .
    Femoxetine hydrochloride
  • HY-100740A

    AZD-3293 hydrochloride; LY3314814 hydrochloride

    Beta-secretase Neurological Disease
    Lanabecestat (AZD-3293) hydrochloride is a potent BACE1 inhibitor that has been investigated for its potential as a modifying treatment for Alzheimer's disease. Lanabecestat (hydrochloride) demonstrated significant dose- and time-dependent reductions in concentrations of amyloid beta peptides in plasma, cerebrospinal fluid, and brain. Lanabecestat (hydrochloride) was also shown to produce reductions in Aβ neuritic plaque burden without demonstrating clinical benefits or slowing the progression of Alzheimer's disease pathophysiology.
    Lanabecestat hydrochloride
  • HY-19752

    CID-25010775 free base

    mAChR Neurological Disease
    VU0357017 (CID-25010775) is a potent, selective and brain-penetrant allosteric agonist of M1 muscarinic acetylcholine receptor, with an EC50 of 477 nM. VU0357017 is highly selective for M1 and has no activity at M2-M5 up to the highest concentrations tested (30 μM). VU0357017 can be used for the research of Alzheimer’s disease and schizophrenia .
    VU0357017
  • HY-19752A

    CID-25010775

    mAChR Neurological Disease
    VU0357017 hydrochloride (CID-25010775) is a potent, selective and brain-penetrant allosteric agonist of M1 muscarinic acetylcholine receptor, with an EC50 of 477 nM. VU0357017 hydrochloride is highly selective for M1 and has no activity at M2-M5 up to the highest concentrations tested (30 μM). VU0357017 hydrochloride can be used for the research of Alzheimer’s disease and schizophrenia .
    VU0357017 hydrochloride
  • HY-108615

    GPi 819

    Phosphorylase Endocrinology
    CP 316819 is a potent glycogen phosphorylase (GPase) inhibitor with antihyperglycemic effect (IC50 values are 17 and 34 nM against human skeletal muscle glycogen phosphorylase (huSMGPa) and liver glycogen phosphorylase (huLGPa) respectively).CP 316819 causes glycogen accumulation under normoglycemic conditions but permits glycogen utilization when glucose concentrations are low.CP-316819 prevents neuronal cell death and maintains brain electrical currents .
    CP-316819
  • HY-167876

    PI3K Cancer
    PQR514 is a potent PI3K inhibitor with anticancer activity. PQR514 is able to inhibit cancer cell proliferation. PQR514 showed significant antitumor activity in the OVCAR-3 xenograft model, with the required concentration being approximately one-eighth that of PQR309. PQR514 has good pharmacokinetic properties and minimal brain penetration, making it an optimized candidate compound for inhibiting systemic tumors .
    PQR514
  • HY-N6951R

    Reference Standards Apoptosis Akt mTOR Reactive Oxygen Species (ROS) Caspase Bacterial Fungal Infection Neurological Disease Inflammation/Immunology Cancer
    Guaiazulene (Standard) is the analytical standard of Guaiazulene (HY-N6951). This product is intended for research and analytical applications. Guaiazulene is a bicyclic sesquiterpene that can cross the blood-brain barrier. Guaiazulene exhibits various biological activities such as anti-inflammatory, antioxidant, hepatoprotective, antibacterial, and anti-tumor properties. Guaiazulene is also commonly used as a colorant in cosmetics. Guaiazulene shows in vitro cytotoxicity to rat neuronal cells and N2a neuroblastoma cells at high concentrations .
    Guaiazulene (Standard)
  • HY-136625

    N-myristoyltransferase Cardiovascular Disease
    LY134046 is an inhibitor of norepinephrine N-methyltransferase (NMT) with cardiovascular activity. LY134046 causes sustained reductions in mean arterial blood pressure and heart rate, but no significant reductions in norepinephrine concentrations in the rat brain. LY134046 does not interact with adrenergic or cholinergic receptors, and its hypotensive and bradycardic effects do not require neurogenic tension. LY134046 (40 mg/kg/day) causes sustained and significant inhibition of hypothalamic and brainstem NMT activity, resulting in central norepinephrine depletion.
    LY134046
  • HY-N2132R

    Flavokavain B (Standard)

    Reference Standards Apoptosis Cancer
    Flavokawain B (Standard) is the analytical standard of Flavokawain B. This product is intended for research and analytical applications. Flavokawain B (Flavokavain B) is a chalcone isolated from the root extracts of kava-kava plant and a potent apoptosis inducer for inhibiting the growth of various cancer cell lines. Flavokawain B (Flavokavain B) shows strong antiangiogenic activity. Flavokawain B (Flavokavain B) inhibits human brain endothelial cell (HUVEC) migration and tube formation with very low and non-toxic concentrations .
    Flavokawain B (Standard)
  • HY-19057

    MK-467; L-659066

    Adrenergic Receptor Cardiovascular Disease Neurological Disease
    Vatinoxan (MK-467) is an alpha 2-adrenergic receptor antagonist. The peripheral selectivity of Vatinoxan determines that it has limited penetration across the blood-brain barrier and therefore has low concentrations in the central nervous system. Vatinoxan antagonizes alpha 2-adrenergic receptor receptors by binding to them, thereby reducing or preventing cardiovascular effects caused by α2-adrenergic agonists. Vatinoxan can be used in studies of cardiovascular effects, sedation and analgesia .
    Vatinoxan

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: